Drugs / L-cysteine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Maapliv | — | 2025-07-28 | europa.eu ↗ |
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04939792 | Nov 2020 → Oct 2022 | vitamin D deficiency | Louisiana State University Health Sciences Center Shreveport | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00004940 | May 1996 → Sep 2001 | erythropoietic protoporphyria | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT02758743 | Apr 2016 → May 2017 | — | Biohit Oyj | Completed | No outcome recorded |
| — | NCT02310828 | Dec 2013 → Feb 2019 | cluster headache syndrome | Biohit Oyj | Completed | No outcome recorded |
| — | NCT02315833 | Dec 2013 → Jul 2019 | migraine disorder | Biohit Oyj | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-cysteine | “Patients are administered L-cysteine orally twice daily, 2 capsules with breakfast and 2 with lunch.” NCT00004940 ↗4“Acetium lozenge (L-cysteine 3mg) is used in context of each cigarette smoked.” NCT02758743 ↗ “Capsule for oral administration contains L-cysteine 100mg” NCT02315833 ↗ “Capsule for oral administration contains L-cysteine 100mg” NCT02310828 ↗ |
| Action | Inhibit | “acetaldehyde, which, in turn, is effectively inactivated by L-cysteine” NCT02310828 ↗ |
| Route | Oral | “administered L-cysteine orally twice daily” NCT00004940 ↗ |